Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
$4.1K
3 trades · 3 insiders
Net · 90d
$-4.1K
Insiders on file
22
Daily buy vs sell · 90 days
■ Open-market buys (P) ■ Open-market sales (S) · daily dollar value by transaction date
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Marshak Richard | Sr.VP, Corp. Dev. & Strategy | 19 | $0 | $51.3K | 2026-10-05 |
| Stevens Jennifer | Chief Regulatory Officer | 14 | $0 | $61.0K | 2026-10-05 |
| Cox Bryan F. | Chief of Research | 15 | $0 | $40.5K | 2026-10-05 |
| Szela Mary T | CEO and President, Director | 24 | $430.0K | $79.4K | 2026-10-05 |
| Patience David | Chief Financial Officer | 8 | $32.2K | $0 | 2026-07-01 |
| Marshall Richard Henry | Chief Medical Officer | 2 | $0 | $0 | 2026-06-29 |
| Gordon Gary B. | Director | 8 | $64.6K | $0 | 2026-05-15 |
| Wahlstrom Mats | Director, 10% Owner | 12 | $221.6K | $0 | 2026-05-15 |
| Stansky Michael P | Director | 8 | $3.01M | $0 | 2026-05-15 |
| Valle William | Director | 7 | $125.0K | $0 | 2026-05-14 |
| MATLIN DAVID J | Director | 13 | $0 | $0 | 2026-05-14 |
| HICKS KERRY R | Director | 5 | $0 | $0 | 2026-05-14 |
| Devlin Jodi | President, Therapeutics | 13 | $0 | $37.8K | 2026-03-16 |
| Frankenius Equity AB | 10% Owner | 4 | $250.0K | $0 | 2025-07-31 |
| Desai Arjun JJ | Director | 6 | $0 | $110.7K | 2025-06-12 |
| Murphy Sean | Director | 11 | $157.2K | $0 | 2025-06-12 |
| Young James Emmett | Chief Financial Officer | 6 | $163.5K | $0 | 2025-05-19 |
| Hyveled Liselotte | Director | 3 | $0 | $0 | 2025-01-02 |
| Martin George Kelly | Director | 3 | $0 | $50 | 2024-08-28 |
| Singhal Anil K. | Director | 2 | $0 | $0 | 2024-08-13 |
| VON ESCHENBACH ANDREW C. | Director | 4 | $0 | $0 | 2024-08-13 |
| Katz Steven C | Chief Medical Officer | 3 | $0 | $0 | 2024-02-12 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Szela Mary T | CEO and President, Director | F Tax w/h | 2026-10-05 | 2026-10-07 | 2,693 | $4.38 | $11.8K | 1,074,990 | SEC↗ |
| Stevens Jennifer | Chief Regulatory Officer | S Sale | 2026-10-05 | 2026-10-07 | 316 | $4.39 | $1.4K | 123,794 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | S Sale | 2026-10-05 | 2026-10-07 | 325 | $4.39 | $1.4K | 127,994 | SEC↗ |
| Cox Bryan F. | Chief of Research | S Sale | 2026-10-05 | 2026-10-07 | 296 | $4.39 | $1.3K | 162,805 | SEC↗ |
| Patience David | Chief Financial Officer | F Tax w/h | 2026-07-01 | 2026-07-06 | 14,650 | $4.46 | $65.3K | 261,107 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | A Award | 2026-06-30 | 2026-07-01 | 561 | $3.87 | $2.2K | 128,319 | SEC↗ |
| Szela Mary T | CEO and President | A Award | 2026-06-30 | 2026-07-01 | 3,990 | $3.87 | $15.4K | 1,077,683 | SEC↗ |
| Marshall Richard Henry | Chief Medical Officer | A Award deriv | 2026-06-29 | 2026-06-29 | 120,000 | — | $0 | 253,000 | SEC↗ |
| Marshall Richard Henry | Chief Medical Officer | A Award | 2026-06-29 | 2026-06-29 | 60,000 | — | $0 | 90,000 | SEC↗ |
| Gordon Gary B. | Director | P Buy | 2026-05-15 | 2026-05-18 | 10,000 | $2.46 | $24.6K | 72,510 | SEC↗ |
| Patience David | Chief Financial Officer | P Buy | 2026-05-15 | 2026-05-18 | 7,100 | $2.43 | $17.3K | 275,757 | SEC↗ |
| Szela Mary T | CEO and President | P Buy | 2026-05-15 | 2026-05-18 | 39,682 | $2.59 | $102.8K | 1,065,215 | SEC↗ |
| Stansky Michael P | Director | P Buy | 2026-05-15 | 2026-05-18 | 200,000 | $2.50 | $500.0K | 399,698 | SEC↗ |
| Stansky Michael P | Director | P Buy | 2026-05-15 | 2026-05-18 | 410,000 | $2.50 | $1.02M | 1,240,722 | SEC↗ |
| Wahlstrom Mats | Director | P Buy | 2026-05-15 | 2026-05-18 | 60,000 | $2.53 | $151.8K | 147,555 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | S Sale | 2026-05-15 | 2026-05-19 | 543 | $2.67 | $1.4K | 125,101 | SEC↗ |
| Stansky Michael P | Director | A Award deriv | 2026-05-14 | 2026-05-15 | 47,003 | — | $0 | 139,540 | SEC↗ |
| Valle William | Director | A Award deriv | 2026-05-14 | 2026-05-15 | 56,403 | — | $0 | 112,653 | SEC↗ |
| MATLIN DAVID J | Director | A Award deriv | 2026-05-14 | 2026-05-15 | 56,403 | — | $0 | 121,403 | SEC↗ |
| Gordon Gary B. | Director | A Award deriv | 2026-05-14 | 2026-05-15 | 56,403 | — | $0 | 112,653 | SEC↗ |
| Wahlstrom Mats | Director | A Award deriv | 2026-05-14 | 2026-05-15 | 75,204 | — | $0 | 276,149 | SEC↗ |
| HICKS KERRY R | Director | A Award deriv | 2026-05-14 | 2026-05-15 | 56,403 | — | $0 | 145,625 | SEC↗ |
| Stansky Michael P | Director | A Award | 2026-05-14 | 2026-05-15 | 23,501 | — | $0 | 810,633 | SEC↗ |
| Stansky Michael P | Director | A Award | 2026-05-14 | 2026-05-15 | 20,089 | — | $0 | 830,722 | SEC↗ |
| Valle William | Director | A Award | 2026-05-14 | 2026-05-15 | 24,553 | — | $0 | 83,241 | SEC↗ |
| Valle William | Director | A Award | 2026-05-14 | 2026-05-15 | 28,201 | — | $0 | 58,688 | SEC↗ |
| MATLIN DAVID J | Director | A Award | 2026-05-14 | 2026-05-15 | 28,201 | — | $0 | 1,300,145 | SEC↗ |
| MATLIN DAVID J | Director | A Award | 2026-05-14 | 2026-05-15 | 23,065 | — | $0 | 1,323,210 | SEC↗ |
| Gordon Gary B. | Director | A Award | 2026-05-14 | 2026-05-15 | 28,201 | — | $0 | 37,957 | SEC↗ |
| Gordon Gary B. | Director | A Award | 2026-05-14 | 2026-05-15 | 24,553 | — | $0 | 62,510 | SEC↗ |
| Wahlstrom Mats | Director | A Award | 2026-05-14 | 2026-05-15 | 34,226 | — | $0 | 87,555 | SEC↗ |
| Wahlstrom Mats | Director | A Award | 2026-05-14 | 2026-05-15 | 37,602 | — | $0 | 53,329 | SEC↗ |
| HICKS KERRY R | Director | A Award | 2026-05-14 | 2026-05-15 | 28,201 | — | $0 | 542,790 | SEC↗ |
| Szela Mary T | CEO and President | S Sale | 2026-03-17 | 2026-03-20 | 15,944 | $3.85 | $61.4K | 752,987 | SEC↗ |
| Stevens Jennifer | Chief Regulatory Officer | S Sale | 2026-03-16 | 2026-03-20 | 774 | $4.12 | $3.2K | 124,110 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | S Sale | 2026-03-16 | 2026-03-20 | 419 | $4.12 | $1.7K | 110,397 | SEC↗ |
| Cox Bryan F. | Chief of Research | S Sale | 2026-03-16 | 2026-03-20 | 579 | $4.12 | $2.4K | 163,415 | SEC↗ |
| Devlin Jodi | Chief of Clinical Operations | S Sale | 2026-03-16 | 2026-03-20 | 273 | $4.12 | $1.1K | 97,364 | SEC↗ |
| Stevens Jennifer | Chief Regulatory Officer | S Sale | 2026-03-12 | 2026-03-20 | 1,552 | $4.09 | $6.3K | 124,884 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | S Sale | 2026-03-12 | 2026-03-20 | 1,589 | $4.09 | $6.5K | 110,816 | SEC↗ |
| Cox Bryan F. | Chief of Research | S Sale | 2026-03-12 | 2026-03-20 | 1,467 | $4.09 | $6.0K | 163,994 | SEC↗ |
| Devlin Jodi | Chief of Clinical Operations | S Sale | 2026-03-12 | 2026-03-20 | 1,772 | $4.09 | $7.2K | 97,637 | SEC↗ |
| Szela Mary T | CEO and President | S Sale | 2026-03-11 | 2026-03-20 | 4,358 | $4.13 | $18.0K | 768,931 | SEC↗ |
| Stevens Jennifer | Chief Regulatory Officer | S Sale | 2026-03-11 | 2026-03-20 | 1,204 | $4.13 | $5.0K | 126,436 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | S Sale | 2026-03-11 | 2026-03-20 | 1,449 | $4.13 | $6.0K | 112,405 | SEC↗ |
| Cox Bryan F. | Chief of Research | S Sale | 2026-03-11 | 2026-03-20 | 1,138 | $4.13 | $4.7K | 165,461 | SEC↗ |
| Devlin Jodi | Chief of Clinical Operations | S Sale | 2026-03-11 | 2026-03-20 | 1,162 | $4.13 | $4.8K | 99,409 | SEC↗ |
| Stansky Michael P | Director | P Buy | 2026-02-23 | 2026-02-23 | 117,198 | $4.10 | $480.5K | 199,698 | SEC↗ |
| Stansky Michael P | Director | P Buy | 2026-02-23 | 2026-02-23 | 243,900 | $4.10 | $1000.0K | 787,132 | SEC↗ |
| Szela Mary T | CEO and President | P Buy | 2026-02-23 | 2026-02-23 | 30,487 | $4.10 | $125.0K | 773,289 | SEC↗ |
| Valle William | Director | P Buy | 2026-02-23 | 2026-02-23 | 30,487 | $4.10 | $125.0K | 30,487 | SEC↗ |
| Gordon Gary B. | Director | P Buy | 2026-02-23 | 2026-02-23 | 9,756 | $4.10 | $40.0K | 9,756 | SEC↗ |
| Patience David | Chief Financial Officer | P Buy | 2026-02-23 | 2026-02-23 | 3,657 | $4.10 | $15.0K | 268,657 | SEC↗ |
| Stansky Michael P | Director | A Award deriv | 2026-02-04 | 2026-02-11 | 92,537 | — | $0 | 92,537 | SEC↗ |
| Patience David | Chief Financial Officer | A Award deriv | 2025-11-24 | 2025-11-25 | 130,000 | — | $0 | 668,899 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | A Award deriv | 2025-11-24 | 2025-11-25 | 120,000 | — | $0 | 408,937 | SEC↗ |
| Stevens Jennifer | Chief Regulatory Officer | A Award deriv | 2025-11-24 | 2025-11-25 | 100,000 | — | $0 | 323,782 | SEC↗ |
| Szela Mary T | CEO and President | A Award deriv | 2025-11-24 | 2025-11-25 | 250,000 | — | $0 | 1,578,182 | SEC↗ |
| Devlin Jodi | Chief of Clinical Operations | A Award deriv | 2025-11-24 | 2025-11-25 | 100,000 | — | $0 | 463,750 | SEC↗ |
| Cox Bryan F. | Chief of Research | A Award deriv | 2025-11-24 | 2025-11-25 | 80,000 | — | $0 | 261,954 | SEC↗ |
| Patience David | Chief Financial Officer | A Award | 2025-11-24 | 2025-11-25 | 65,000 | — | $0 | 265,000 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | A Award | 2025-11-24 | 2025-11-25 | 60,000 | — | $0 | 113,854 | SEC↗ |
| Stevens Jennifer | Chief Regulatory Officer | A Award | 2025-11-24 | 2025-11-25 | 50,000 | — | $0 | 127,640 | SEC↗ |
| Szela Mary T | CEO and President | A Award | 2025-11-24 | 2025-11-25 | 125,000 | — | $0 | 442,802 | SEC↗ |
| Szela Mary T | CEO and President | A Award | 2025-11-24 | 2025-11-25 | 300,000 | — | $0 | 742,802 | SEC↗ |
| Devlin Jodi | Chief of Clinical Operations | A Award | 2025-11-24 | 2025-11-25 | 50,000 | — | $0 | 100,571 | SEC↗ |
| Cox Bryan F. | Chief of Research | A Award | 2025-11-24 | 2025-11-25 | 40,000 | — | $0 | 166,599 | SEC↗ |
| Patience David | Chief Financial Officer | A Award deriv | 2025-08-28 | 2025-08-29 | 248,899 | — | $0 | 538,899 | SEC↗ |
| Patience David | Chief Financial Officer | A Award deriv | 2025-08-14 | 2025-08-15 | 290,000 | — | $0 | 290,000 | SEC↗ |
| Patience David | Chief Financial Officer | A Award | 2025-08-14 | 2025-08-15 | 200,000 | — | $0 | 200,000 | SEC↗ |
| MATLIN DAVID J | Director | C Conversion deriv | 2025-07-31 | 2026-04-01 | 100,000 | — | $0 | 0 | SEC↗ |
| Frankenius Equity AB | 10% Owner | C Conversion deriv | 2025-07-31 | 2026-04-20 | 230,000 | — | $0 | 0 | SEC↗ |
| MATLIN DAVID J | Director | C Conversion | 2025-07-31 | 2026-04-01 | 330,000 | — | $0 | 1,271,944 | SEC↗ |
| Frankenius Equity AB | 10% Owner | C Conversion | 2025-07-31 | 2026-04-20 | 759,000 | — | $0 | 6,989,748 | SEC↗ |
| Wahlstrom Mats | Director | A Award deriv | 2025-06-12 | 2025-06-27 | 15,000 | — | $0 | 200,945 | SEC↗ |
| Valle William | Director | A Award deriv | 2025-06-12 | 2025-06-27 | 15,000 | — | $0 | 56,250 | SEC↗ |
| Murphy Sean | Director | A Award deriv | 2025-06-12 | 2025-06-27 | 15,000 | — | $0 | 554,681 | SEC↗ |
| MATLIN DAVID J | Director | A Award deriv | 2025-06-12 | 2025-06-27 | 15,000 | — | $0 | 65,000 | SEC↗ |
| HICKS KERRY R | Director | A Award deriv | 2025-06-12 | 2025-06-27 | 15,000 | — | $0 | 89,222 | SEC↗ |
| Gordon Gary B. | Director | A Award deriv | 2025-06-12 | 2025-06-27 | 15,000 | — | $0 | 56,250 | SEC↗ |
| Desai Arjun JJ | Director | A Award deriv | 2025-06-12 | 2025-06-27 | 15,000 | — | $0 | 65,000 | SEC↗ |
| Stevens Jennifer | Chief Regulatory Officer | S Sale | 2025-05-19 | 2025-05-21 | 8,704 | $5.18 | $45.1K | 77,640 | SEC↗ |
| Stevens Jennifer | Chief Regulatory Officer | A Award | 2025-05-19 | 2025-05-21 | 28,455 | $5.18 | $147.4K | 86,344 | SEC↗ |
| Murphy Sean | Director | A Award | 2025-05-19 | 2025-05-21 | 44,884 | $5.18 | $232.5K | 123,989 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | A Award | 2025-05-19 | 2025-05-21 | 21,428 | $5.18 | $111.0K | 75,698 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | S Sale | 2025-05-19 | 2025-05-21 | 6,597 | $5.18 | $34.2K | 69,101 | SEC↗ |
| Devlin Jodi | Chief of Clinical Operations | S Sale | 2025-05-19 | 2025-05-21 | 4,764 | $5.18 | $24.7K | 52,764 | SEC↗ |
| Devlin Jodi | Chief of Clinical Operations | A Award | 2025-05-19 | 2025-05-21 | 24,131 | $5.18 | $125.0K | 57,528 | SEC↗ |
| Cox Bryan F. | Chief of Research | S Sale | 2025-05-19 | 2025-05-21 | 4,764 | $5.18 | $24.7K | 119,415 | SEC↗ |
| Cox Bryan F. | Chief of Research | A Award | 2025-05-19 | 2025-05-21 | 15,722 | $5.18 | $81.4K | 124,179 | SEC↗ |
| Young James Emmett | Chief Financial Officer | A Award | 2025-05-19 | 2025-05-21 | 13,175 | $5.18 | $68.2K | 49,663 | SEC↗ |
| Devlin Jodi | Chief of Clinical Operations | A Award | 2025-02-18 | 2025-02-19 | 5,272 | — | $0 | 33,397 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | A Award | 2025-02-18 | 2025-02-19 | 21,089 | — | $0 | 465,348 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | A Award | 2025-02-18 | 2025-02-19 | 7,644 | — | $0 | 54,270 | SEC↗ |
| Cox Bryan F. | CHIEF OF RESEARCH | A Award | 2025-02-18 | 2025-02-19 | 11,450 | — | $0 | 108,457 | SEC↗ |
| Stevens Jennifer | CHIEF REGULATORY OFFICER | A Award | 2025-02-18 | 2025-02-19 | 14,481 | — | $0 | 57,889 | SEC↗ |
| Young James Emmett | Chief Financial Officer | A Award | 2025-02-18 | 2025-02-19 | 14,762 | — | $0 | 36,488 | SEC↗ |
| Murphy Sean | Chief Manuf, Strategy&Bus De | A Award | 2025-02-18 | 2025-02-19 | 15,817 | — | $0 | 79,105 | SEC↗ |
| Frankenius Equity AB | 10% Owner | J Other deriv | 2025-02-10 | 2025-02-11 | 205,853 | — | $0 | 435,853 | SEC↗ |
| Wahlstrom Mats | Director, 10% Owner | J Other deriv | 2025-02-10 | 2025-02-11 | 44,750 | — | $0 | 94,750 | SEC↗ |
| MATLIN DAVID J | Director | J Other deriv | 2025-02-10 | 2025-02-11 | 89,501 | — | $0 | 189,501 | SEC↗ |
| Young James Emmett | Chief Financial Officer | P Buy | 2025-02-05 | 2025-02-06 | 6,000 | $5.65 | $33.9K | 30,000 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | P Buy | 2025-01-30 | 2025-01-31 | 5,010 | $5.28 | $26.5K | 444,259 | SEC↗ |
| Valle William | Director | A Award deriv | 2025-01-29 | 2025-01-31 | 6,250 | — | $0 | 6,250 | SEC↗ |
| Valle William | Director | A Award deriv | 2025-01-29 | 2025-01-31 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Gordon Gary B. | Director | A Award deriv | 2025-01-29 | 2025-01-31 | 6,250 | — | $0 | 6,250 | SEC↗ |
| Gordon Gary B. | Director | A Award deriv | 2025-01-29 | 2025-01-31 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | P Buy | 2025-01-29 | 2025-01-31 | 5,030 | $5.03 | $25.3K | 439,249 | SEC↗ |
| Murphy Sean | Chief Manuf, Strategy&Bus De | P Buy | 2025-01-28 | 2025-01-29 | 15,000 | $5.17 | $77.5K | 197,732 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | P Buy | 2025-01-28 | 2025-01-29 | 4,716 | $5.12 | $24.1K | 434,219 | SEC↗ |
| Stevens Jennifer | CHIEF REGULATORY OFFICER | A Award deriv | 2025-01-27 | 2025-01-29 | 63,750 | — | $0 | 63,750 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | A Award deriv | 2025-01-27 | 2025-01-29 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Devlin Jodi | Chief of COMMERC. OPERATIONS | A Award deriv | 2025-01-27 | 2025-01-29 | 63,750 | — | $0 | 63,750 | SEC↗ |
| Young James Emmett | Chief Financial Officer | A Award deriv | 2025-01-27 | 2025-01-29 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Cox Bryan F. | CHIEF OF RESEARCH | A Award deriv | 2025-01-27 | 2025-01-29 | 63,750 | — | $0 | 63,750 | SEC↗ |
| Murphy Sean | Chief Manuf, Strategy&Bus De | A Award deriv | 2025-01-27 | 2025-01-29 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | A Award deriv | 2025-01-27 | 2025-01-29 | 240,000 | — | $0 | 240,000 | SEC↗ |
| Stevens Jennifer | CHIEF REGULATORY OFFICER | A Award | 2025-01-27 | 2025-01-29 | 10,625 | — | $0 | 43,408 | SEC↗ |
| Marshak Richard | Chief Commercial Officer | A Award | 2025-01-27 | 2025-01-29 | 12,500 | — | $0 | 46,626 | SEC↗ |
| Devlin Jodi | Chief of COMMERC. OPERATIONS | A Award | 2025-01-27 | 2025-01-29 | 10,625 | — | $0 | 28,125 | SEC↗ |
| Young James Emmett | Chief Financial Officer | A Award | 2025-01-27 | 2025-01-29 | 12,500 | — | $0 | 21,726 | SEC↗ |
| Young James Emmett | Chief Financial Officer | P Buy | 2025-01-27 | 2025-01-29 | 24,000 | $5.40 | $129.6K | 24,000 | SEC↗ |
| Cox Bryan F. | CHIEF OF RESEARCH | A Award | 2025-01-27 | 2025-01-29 | 10,625 | — | $0 | 97,007 | SEC↗ |
| Murphy Sean | Chief Manuf, Strategy&Bus De | A Award | 2025-01-27 | 2025-01-29 | 12,500 | — | $0 | 63,288 | SEC↗ |
| Murphy Sean | Chief Manuf, Strategy&Bus De | P Buy | 2025-01-27 | 2025-01-29 | 15,000 | $5.31 | $79.7K | 182,732 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | A Award | 2025-01-27 | 2025-01-29 | 40,000 | — | $0 | 424,677 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | P Buy | 2025-01-27 | 2025-01-29 | 4,826 | $5.42 | $26.2K | 429,503 | SEC↗ |
| Hyveled Liselotte | Director | A Award | 2025-01-02 | 2025-01-06 | 10,040 | — | $0 | 10,040 | SEC↗ |
| MATLIN DAVID J | Director | A Award | 2025-01-02 | 2025-01-06 | 10,040 | — | $0 | 941,944 | SEC↗ |
| Frankenius Equity AB | 10% Owner | P Buy | 2024-12-17 | 2024-12-19 | 62,972 | $3.97 | $250.0K | 6,230,748 | SEC↗ |
| Wahlstrom Mats | Director, 10% Owner | A Award | 2024-12-17 | 2024-12-19 | 25,188 | $3.97 | $100.0K | 40,915 | SEC↗ |
| Desai Arjun JJ | Director | S Sale | 2024-12-10 | 2024-12-12 | 30,000 | $3.69 | $110.7K | 247,127 | SEC↗ |
| Wahlstrom Mats | Director, 10% Owner | P Buy | 2024-11-22 | 2024-11-25 | 5,000 | $4.55 | $22.8K | 15,727 | SEC↗ |
| Wahlstrom Mats | Director, 10% Owner | P Buy | 2024-11-21 | 2024-11-22 | 8,687 | $4.44 | $38.6K | 10,727 | SEC↗ |
| Wahlstrom Mats | Director, 10% Owner | P Buy | 2024-11-20 | 2024-11-22 | 2,040 | $4.16 | $8.5K | 2,040 | SEC↗ |
| Marshak Richard | SR.VP, CORP. DEV. & STRATEGY | A Award deriv | 2024-11-14 | 2024-11-15 | 41,250 | — | $0 | 41,250 | SEC↗ |
| Marshak Richard | SR.VP, CORP. DEV. & STRATEGY | A Award | 2024-11-14 | 2024-11-15 | 6,875 | — | $0 | 34,126 | SEC↗ |
| Cox Bryan F. | CHIEF SCIENTIFIC & MANUFACT. | S Sale | 2024-10-05 | 2024-12-19 | 314 | $4.44 | $1.4K | 86,382 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | P Buy | 2024-09-13 | 2024-09-13 | 6,000 | $5.00 | $30.0K | 384,677 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | P Buy | 2024-09-13 | 2024-09-13 | 1,295 | $4.83 | $6.3K | 378,677 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | P Buy | 2024-09-12 | 2024-09-13 | 7,520 | $5.20 | $39.1K | 377,382 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | P Buy | 2024-09-10 | 2024-09-12 | 5,000 | $4.97 | $24.9K | 369,862 | SEC↗ |
| Martin George Kelly | Director | S Sale | 2024-08-28 | 2024-09-10 | 9 | $5.50 | $50 | 247,176 | SEC↗ |
| VON ESCHENBACH ANDREW C. | Director | A Award deriv | 2024-08-13 | 2024-08-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Singhal Anil K. | Director | A Award deriv | 2024-08-13 | 2024-08-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Desai Arjun JJ | Director | A Award deriv | 2024-08-13 | 2024-08-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| MATLIN DAVID J | Director | A Award deriv | 2024-08-13 | 2024-08-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Martin George Kelly | Director | A Award deriv | 2024-08-13 | 2024-08-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| HICKS KERRY R | Director | A Award deriv | 2024-08-13 | 2024-08-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Hyveled Liselotte | Director | A Award deriv | 2024-08-13 | 2024-08-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Wahlstrom Mats | Director, 10% Owner | A Award deriv | 2024-08-13 | 2024-08-21 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Desai Arjun JJ | Director | D To issuer deriv | 2024-07-01 | 2024-07-02 | 246,667 | — | $0 | 0 | SEC↗ |
| Desai Arjun JJ | Director | A Award | 2024-07-01 | 2024-07-02 | 74,000 | — | $0 | 277,127 | SEC↗ |
| VON ESCHENBACH ANDREW C. | Director | G Gift deriv | 2024-06-03 | 2024-06-05 | 35,000 | — | $0 | 0 | SEC↗ |
| VON ESCHENBACH ANDREW C. | Director | G Gift deriv | 2024-06-03 | 2024-06-05 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Hyveled Liselotte | Director | A Award deriv | 2024-05-06 | 2024-05-07 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Szela Mary T | CEO and President | A Award | 2024-02-13 | 2025-11-25 | 125,000 | — | $0 | 317,802 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | A Award deriv | 2024-02-13 | 2024-02-14 | 288,750 | — | $0 | 288,750 | SEC↗ |
| Szela Mary T | CEO AND PRESIDENT | A Award | 2024-02-13 | 2024-02-14 | 84,899 | — | $0 | 364,862 | SEC↗ |
| Katz Steven C | CHIEF MEDICAL OFFICER | A Award deriv | 2024-02-12 | 2024-02-14 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Murphy Sean | CHIEF FINANCIAL OFFICER | A Award deriv | 2024-02-12 | 2024-02-14 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Devlin Jodi | PRESIDENT, COMMERC. OPERATIO | A Award deriv | 2024-02-12 | 2024-02-14 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Stevens Jennifer | CHIEF REGULATORY OFFICER | A Award deriv | 2024-02-12 | 2024-02-14 | 63,750 | — | $0 | 63,750 | SEC↗ |
| Cox Bryan F. | CHIEF SCIENTIFIC & MANUFACT. | A Award deriv | 2024-02-12 | 2024-02-14 | 63,750 | — | $0 | 63,750 | SEC↗ |
| Marshak Richard | SR.VP, CORP. DEV. & STRATEGY | A Award deriv | 2024-02-12 | 2024-02-14 | 63,750 | — | $0 | 63,750 | SEC↗ |
| Katz Steven C | CHIEF MEDICAL OFFICER | A Award | 2024-02-12 | 2024-02-14 | 34,144 | — | $0 | 68,587 | SEC↗ |
| Murphy Sean | CHIEF FINANCIAL OFFICER | A Award | 2024-02-12 | 2024-02-14 | 34,144 | — | $0 | 50,788 | SEC↗ |
| Devlin Jodi | PRESIDENT, COMMERC. OPERATIO | A Award | 2024-02-12 | 2024-02-14 | 17,500 | — | $0 | 17,500 | SEC↗ |
| Stevens Jennifer | CHIEF REGULATORY OFFICER | A Award | 2024-02-12 | 2024-02-14 | 14,752 | — | $0 | 32,783 | SEC↗ |
| Cox Bryan F. | CHIEF SCIENTIFIC & MANUFACT. | A Award | 2024-02-12 | 2024-02-14 | 14,752 | — | $0 | 86,696 | SEC↗ |
| Marshak Richard | SR.VP, CORP. DEV. & STRATEGY | A Award | 2024-02-12 | 2024-02-14 | 14,752 | — | $0 | 27,251 | SEC↗ |
| Marshak Richard | SR.VP, CORP. DEV. & STRATEGY | A Award deriv | 2024-01-24 | 2024-01-25 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Murphy Sean | CHIEF FINANCIAL OFFICER | A Award deriv | 2024-01-24 | 2024-01-25 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Devlin Jodi | President, Therapeutics | A Award deriv | 2023-08-30 | 2023-08-31 | 195,000 | — | $0 | 195,000 | SEC↗ |
| Szela Mary T | CEO and President | A Award deriv | 2023-08-14 | 2023-08-15 | 172,500 | — | $0 | 172,500 | SEC↗ |
| Cox Bryan F. | Chief Scientific & Manufact. | A Award deriv | 2023-08-11 | 2023-08-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Katz Steven C | Chief Medical Officer | A Award deriv | 2023-08-11 | 2023-08-14 | 62,500 | — | $0 | 62,500 | SEC↗ |
| Marshak Richard | Sr.VP, Corp. Dev. & Strategy | A Award deriv | 2023-08-11 | 2023-08-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Murphy Sean | Chief Financial Officer | A Award deriv | 2023-08-11 | 2023-08-14 | 62,500 | — | $0 | 62,500 | SEC↗ |
| Stevens Jennifer | Chief Regulatory Officer | A Award deriv | 2023-08-11 | 2023-08-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Desai Arjun JJ | Director | A Award deriv | 2023-08-10 | 2023-08-14 | 35,000 | — | $0 | 35,000 | SEC↗ |
| HICKS KERRY R | Director | A Award deriv | 2023-08-10 | 2023-08-14 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Martin George Kelly | Director | A Award deriv | 2023-08-10 | 2023-08-14 | 35,000 | — | $0 | 35,000 | SEC↗ |
| MATLIN DAVID J | Director | A Award deriv | 2023-08-10 | 2023-08-14 | 100,000 | $10.00 | $1.00M | 100,000 | SEC↗ |
| MATLIN DAVID J | Director | A Award deriv | 2023-08-10 | 2023-08-14 | 35,000 | — | $0 | 35,000 | SEC↗ |
| MATLIN DAVID J | Director | J Other deriv | 2023-08-10 | 2023-08-14 | 1,240,518 | — | $0 | 1,240,518 | SEC↗ |
| Singhal Anil K. | Director | A Award deriv | 2023-08-10 | 2023-08-14 | 35,000 | — | $0 | 35,000 | SEC↗ |
| VON ESCHENBACH ANDREW C. | Director | A Award deriv | 2023-08-10 | 2023-08-14 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Wahlstrom Mats | Director, 10% Owner | A Award deriv | 2023-08-10 | 2023-08-14 | 35,000 | — | $0 | 35,000 | SEC↗ |
| MATLIN DAVID J | Director | J Other | 2023-08-10 | 2023-08-14 | 931,904 | — | $0 | 931,904 | SEC↗ |